NANS Protein Stabilizes LATS2, Fueling Growth and Treatment Resistance in Breast Cancer
A recent study has identified a novel mechanism by which the enzyme NANS plays a crucial role in the progression of HR+/HER2- breast cancer. Researchers discovered that NANS, independent of its enzymatic function, stabilizes the LATS2 protein. This stabilization of LATS2 is a key driver for tumor growth and contributes significantly to therapeutic resistance in this specific subtype of breast cancer. The findings suggest that targeting the interaction between NANS and LATS2 could offer a new avenue for treating patients with HR+/HER2- breast cancer who often face limited treatment options due to resistance. Further research into this pathway may lead to the development of more effective therapeutic strategies aimed at overcoming treatment resistance and improving patient outcomes. The study highlights the complex molecular landscape of breast cancer and the importance of understanding non-enzymatic roles of proteins in disease progression.
This research uncovers a non-enzymatic function of NANS, demonstrating its capacity to stabilize LATS2 and thereby promote tumor growth and treatment resistance in HR+/HER2- breast cancer. This finding shifts focus from NANS's catalytic activity to its structural or scaffolding role, suggesting that therapeutic strategies may need to target protein-protein interactions rather than enzyme inhibition alone. The implications for the next decade are significant, as understanding such complex regulatory mechanisms is crucial for developing next-generation cancer therapies. By identifying this pathway, researchers are providing a potential leverage point to overcome resistance, a major challenge in oncology. Future work could explore the systemic implications of targeting this interaction, considering potential off-target effects and the broader impact on cellular processes, aiming to enhance therapeutic efficacy without compromising patient safety.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.